Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-AMT-060-04 long-term extension of AAV5-hFIX (Hemgenix) in haemophilia B
2024-512603-39-00Phase 2Completed
- Sponsor
- CSL Behring
- Start
- Jun 2024
- Modality
- Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of etranacogene dezaparvovec in hemophilia B (HB), sponsored by CSL Behring. Primary endpoints: Long-term safety 6–10 years after CSL220 dosing, Adverse events related to prior CSL220 administration and 4 more. Started Jun 2024; status: completed.
02
Drugs
etranacogene dezaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2024-512603-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512603-39-00.